美国 · SEC FORM 4
PTC THERAPEUTICS, INC.
PTCT · Nasdaq · CIK 0001070081 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
108 同一窗口内观察到的 Form 4 交易行
76 sales · 32 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-12-12 · Gravier Pierre.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 9,168,333
- 上期报告
- 9,738,919
- 日均成交量
- 1,493,955
- 回补天数
- 6.1
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
Form 4 申报证据
297 transaction lines in the latest 365-day window; 1,099 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 2,500 | USD 59.61 | USD 149,037 | SEC 申报 ↗ |
| 2026-10-09 | Boulding Mark Elliott | 卖出 (S) | Common Stock | 192 | USD 64.26 | USD 12,338 | SEC 申报 ↗ |
| 2026-10-09 | Boulding Mark Elliott | 期权行权/转换 (M) | Common Stock | 192 | USD 39.42 | USD 7,569 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 2,500 | USD 59.61 | USD 149,037 | SEC 申报 ↗ |
| 2026-10-09 | Boulding Mark Elliott | 卖出 (S) | Common Stock | 192 | USD 64.26 | USD 12,338 | SEC 申报 ↗ |
| 2026-10-09 | Boulding Mark Elliott | 期权行权/转换 (M) | Common Stock | 192 | USD 39.42 | USD 7,569 | SEC 申报 ↗ |
| 2026-10-07 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 2,500 | USD 63.39 | USD 158,480 | SEC 申报 ↗ |
| 2026-10-06 | Boulding Mark Elliott | 卖出 (S) | Common Stock | 435 | USD 64.16 | USD 27,910 | SEC 申报 ↗ |
| 2026-10-06 | Boulding Mark Elliott | 期权行权/转换 (M) | Common Stock | 435 | USD 39.42 | USD 17,148 | SEC 申报 ↗ |
| 2026-10-05 | Boulding Mark Elliott | 卖出 (S) | Common Stock | 1,638 | USD 64.03 | USD 104,881 | SEC 申报 ↗ |
| 2026-10-05 | Boulding Mark Elliott | 期权行权/转换 (M) | Common Stock | 1,638 | USD 39.42 | USD 64,570 | SEC 申报 ↗ |
| 2026-09-30 | STEELE GLENN JR MD PHD | 卖出 (S) | Common Stock | 12,000 | USD 65.16 | USD 781,920 | SEC 申报 ↗ |
| 2026-09-30 | STEELE GLENN JR MD PHD | 期权行权/转换 (M) | Common Stock | 12,000 | USD 11.23 | USD 134,760 | SEC 申报 ↗ |
| 2026-09-17 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 10,000 | USD 67.85 | USD 678,533 | SEC 申报 ↗ |
| 2026-09-16 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 10,000 | USD 67.12 | USD 671,195 | SEC 申报 ↗ |
| 2026-09-10 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 10,000 | USD 67.34 | USD 673,400 | SEC 申报 ↗ |
| 2026-09-09 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 10,000 | USD 67.84 | USD 678,403 | SEC 申报 ↗ |
| 2026-08-27 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 12,500 | USD 71.58 | USD 894,784 | SEC 申报 ↗ |
| 2026-08-26 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 12,500 | USD 72.94 | USD 911,725 | SEC 申报 ↗ |
| 2026-08-20 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 12,500 | USD 71.11 | USD 888,858 | SEC 申报 ↗ |
| 2026-08-19 | SCHMERTZLER MICHAEL | 卖出 (S) | Common Stock | 12,500 | USD 73.32 | USD 916,554 | SEC 申报 ↗ |
| 2026-08-17 | Boulding Mark Elliott | 卖出 (S) | Common Stock | 2,813 | USD 72.57 | USD 204,127 | SEC 申报 ↗ |
| 2026-08-17 | Boulding Mark Elliott | 期权行权/转换 (M) | Common Stock | 2,813 | USD 25.69 | USD 72,266 | SEC 申报 ↗ |
| 2026-08-04 | Klein Matthew B. | 卖出 (S) | Common Stock | 10,292 | USD 68.57 | USD 705,722 | SEC 申报 ↗ |
| 2026-07-28 | Sollie-Zetlmayer Hege Elisabeth | 奖励/授予 (A) | Common Stock | 6,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-14 | Gravier Pierre | 卖出 (S) | Common Stock | 3,494 | USD 80.35 | USD 280,743 | SEC 申报 ↗ |
| 2026-07-09 | Smith Mary L. | 卖出 (S) | Common Stock | 15,834 | USD 90.00 | USD 1,425,060 | SEC 申报 ↗ |
| 2026-07-09 | Smith Mary L. | 期权行权/转换 (M) | Common Stock | 15,834 | USD 42.95 | USD 680,070 | SEC 申报 ↗ |
| 2026-07-09 | Almstead Neil Gregory | 卖出 (S) | Common Stock | 2,464 | USD 90.25 | USD 222,376 | SEC 申报 ↗ |
| 2026-07-09 | Almstead Neil Gregory | 期权行权/转换 (M) | Common Stock | 2,464 | USD 46.54 | USD 114,675 | SEC 申报 ↗ |
| 2026-07-07 | Almstead Neil Gregory | 卖出 (S) | Common Stock | 24,613 | USD 88.89 | USD 2,187,745 | SEC 申报 ↗ |
| 2026-07-07 | Almstead Neil Gregory | 期权行权/转换 (M) | Common Stock | 24,613 | USD 39.42 | USD 970,244 | SEC 申报 ↗ |
| 2026-07-06 | Boulding Mark Elliott | 卖出 (S) | Common Stock | 5,079 | USD 85.08 | USD 432,118 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PTCT |
| CIK | 0001070081 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 1,099 transaction lines from 2020-01-02 to 2026-10-14 2 P purchase lines · 705 S sale lines · 392 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.